Report: Pipeline/Commercial Insight: Supportive Care in Oncology - Significant growth opportunities exist in new supportive care indications TOC

ABOUT DATAMONITOR HEALTHCARE
- About the Oncology pharmaceutical analysis team
  - Andrew Paramore - Oncology Lead Analyst & Head of Product Development
CHAPTER 1 EXECUTIVE SUMMARY
- Objective of the analysis
- Datamonitor insight into the oncology supportive care market
- Related reports
- Upcoming reports
CHAPTER 2 PIPELINE OVERVIEW
- Pipeline overview
- Pipeline by developmental phase and indication
  - The oncology supportive care pipeline in its entirety is relatively sparse
  - Pipeline split by phase
    - The late-phase pipeline will flourish in the future, as early-stage agents move forward in development
  - Pipeline split by indication
    - Chemotherapy-induced nausea and vomiting is the most popular indication in terms of pipeline activity
    - Significant unmet needs in the cancer-related mucositis market means the early-phase pipeline has increased in activity
    - A greater level of activity would have been expected in the cancer-related thrombocytopenia pipeline
- Pipeline by company
  - At least 67 companies are involved in the oncology supportive care pipeline
    - The high involvement of smaller companies in the oncology supportive care pipeline is not surprising, given that 82% of compounds are in early-phase development
  - The top three companies in terms of marketed and pipeline oncology supportive care products are Amgen, GlaxoSmithKline and Roche
    - Amgen
    - GlaxoSmithKline
    - Roche
- Key metrics
- Datamonitor pipeline assessment summary
CHAPTER 3 MARKET DEFINITION AND PIPELINE DYNAMICS
- Supportive care overview
- Market definition and classification of products
  - A4A - Anti-emetics and anti-nauseants
    - Playing a key role in the prophylaxis and/or treatment of acute and delayed chemotherapy-induced nausea and vomiting
    - Defining the emetic risk of various cytotoxics used to treat cancer
    - Anti-emetic mode of action is conferred by blocking the action of various neuroreceptors
    - Classes of anti-emetic/anti-nauseant
  - B3C - Erythropoiesis-stimulating products
    - Anemia may severely affect patient quality of life
    - Products capable of stimulating the production of red blood cells can be used to treat cancer-related anemia
    - Key erythropoiesis-stimulating products
  - L3A1 - Colony-stimulating factors
    - Neutropenia was potentially fatal before the introduction of current supportive care measures
    - Colony-stimulating factors promote the production of white blood cells to prevent neutropenia
    - Key colony-stimulatings factors
  - L3A9 - All other immunostimulating agents excluding interferons
    - Thrombocytopenia increases the risk of severe bleeding in cancer patients
    - Only one formally approved agent exists for the prevention of thrombocytopenia to date
  - M5B1/M5B2 - Bisphosphonate bone calcium regulators
    - Bone metastases and tumor-induced hypercalcemia can cause significant morbidity in cancer patients
    - Bisphosphonates are used in the prevention and/or treatment of cancer-related skeletal events due to their ability to restore normal balance to bone activity
    - Key bisphosphonates approved for oncology indications
  - V3D0 - Detoxifying agents for antineoplastic treatment
    - Mucositis can result in significant complications, exacerbated by further cancer treatment and any therapy-related nausea and vomiting
    - Use of the only growth factor approved for mucositis to date is restricted by its cost, particularly in more conservative markets
- Current market dynamics
  - A top-line view of the oncology supportive care market
    - The large majority of drug classes underwent significant sales growth between 2005 and 2006
  - The oncology supportive care market by drug class
- Epidemiology
  - Epidemiology of cancer
    - A continuously expanding patient base
    - Increased incidence a consequence of aging populations and lifestyle modifications
  - Epidemiology of supportive care indications
CHAPTER 4 MARKETED PRODUCTS FORECAST ANALYSIS
- Country-specific assumptions and effects
  - Generic pricing and erosion assumptions
- Product assumptions and effects
  - A4A1 - 5-HT3 serotonin receptor antagonists
    - Drug class asumptions
    - Helsinn Pharma/MGI Pharma' s Aloxi (palonosetron)
    - Sanofi-Aventis' s Anzemet (dolasetron)
    - Roche/Chugai' s Kytril (granisetron)
    - Astellas' Nasea (ramosetron)
    - Novartis' s Navoban (tropisetron)
    - Welfide/Japan Tobacco' s Serotone (azasetron)
    - Nisshin Kyorin Pharmaceuticals' Sinseron (indisetron)
    - GlaxoSmithKline' s Zofran (ondansetron)
  - A4A9 - Other anti-emetics/anti-nauseants
    - Merck & Co' s Emend (aprepitant)
  - B3C0 - Erythropoiesis-stimulating products
    - Drug class assumptions
    - Controversy affecting the drug class as a whole
    - Amgen' s Aranesp (darbepoetin alfa)
    - Amgen Epogen/Johnson & Johnson' s Procrit/Kirin' s Eprex (epoetin alfa)
    - Roche' s NeoRecormon (epoetin beta)
  - L3A1 - Colony-stimulating factors
    - Chugai' s Granocyte (lenograstim)
    - Bayer Schering/Berlex' s Leukine (sargramostim)
    - Amgen' s Neulasta (pegfilgrastim)
    - Amgen' s Neupogen (filgrastim)
    - Kyowa Hakko Kogyo' s Neu-Up (nartograstim)
  - L3A9 - Other immunostimulating agents
    - Wyeth' s Neumega (oprelvekin)
  - M5B1/M5B2 - Oral and injectable bisphosphonates
    - Drug class assumptions
    - Proctor & Gamble/Sanofi-Aventis' s Actonel (risedronic acid)
    - Novartis' s Aredia (pamidronic acid)
    - Astellas' Bisphonal (incadronic acid)
    - Roche/GlaxoSmithKline' s Bondronat/Boniva/Bonviva (ibandronic acid)
    - Bayer Schering' s Bonefos (clodronic acid)
    - Novartis' s Zometa (zoledronic acid)
  - V3D0 - Other detoxifying agents for cancer
    - Amgen' s Kepivance (palifermin)
- Forecasts
- Forecast methodology
CHAPTER 5 PIPELINE ANTI-EMETIC PRODUCTS ANALYSIS AND FORECASTS
- Pipeline overview
- Definition of current comparator
  - GlaxoSmithKline' s Zofran (ondansetron)
    - The preferred 5-HT3 receptor antagonist in the seven major markets
- Reckitt Benckiser Healthcare/BioDelivery Sciences' Emezine (reformulated prochlorperazine maleate)
  - Drug profile
    - Issue of a non-approvable letter by the FDA for Emezine may not bode well for the drug' s future
  - Clinical trial data
    - Pharmacokinetic studies indicate that Emezine' s route of administration may result in a higher plasma concentration than traditional formulations
  - Datamonitor comments
    - BioDelivery Sciences believes Emezine to confer advantages by virtue of its formulation
    - The widespread availability of generic prochlorperazine and more efficacious newer anti-emetics means that uptake of Emezine may be limited
- Hana Biosciences/NovaDel Pharma' s Zensana (reformulated ondansetron)
  - Drug profile
    - Long-term stability issues means reformulation of Zensana was necessary, however, this has delayed commercialization
  - Clinical trial data
    - Zensana has been proven bioequivalent to Zofran
    - Surveyed members of the oncology community ranked Zensana highly in terms of potential ease of use
  - Datamonitor comments
    - Zensana confers administration advantages over traditionally formulated ondansetron, however, the drug' s price point should be set with caution
- ProStrakan' s Sancuso (reformulated granisetron)
  - Drug profile
    - Sancuso allows for an alternative route of administration to Kytril
  - Clinical trial data
    - Phase III data show Sancuso to confer comparable efficacy and safety to oral Kytril
  - Datamonitor comments
    - Sancuso must be priced competitively in order to avoid being driven out of the market by generic versions of 5-HT3 anatagonists
- AP Pharma' s APF-530 (reformulated slow-release granisetron)
  - Drug profile
    - Slow-release formulation of granisetron should provide consisent protection against chemotherapy-induced nausea and vomiting
  - Clinical trial data
    - Clinical data support the use of a single injection of APF-530 adminstered 30 minutes before chemotherapy to provide continuous protection
  - Datamonitor comments
    - While generic versions of granisetron will see uptake, APF-530 may lose out somewhat to Sancuso due to its formulation
- GlaxoSmithKline' s casopitant (GW-679769)
  - Drug profile
    - Casopitant could become the second NK-1 antagonist to reach the market
  - Clinical trial data
    - Casopitant in combination with Zofran is effective in patients receiving moderately-emetogenic chemotherapy
    - Varying doses of capositant are effective in preventing nausea and vomiting associated with highly-emetogenic chemotherapy
  - Datamonitor comments
    - Given the youth of the NK-1 antagonist drug class, casopitant could represent a valuable addition to treatment options
- Forecasts
- Datamonitor drug assessment summary
  - Future potential of pipeline anti-emetic products
    - The pipeline anti-emetics will enjoy reasonable uptake and sales, however, no major breakthroughs in the prevention and/or treatment of chemotherapy-induced nausea and vomiting will be provided
CHAPTER 6 PIPELINE ERYTHROPOIESIS-STIMULATING PRODUCTS ANALYSIS AND FORECASTS
- Pipeline overview
- Definition of current comparator
  - Amgen' s Aranesp (darbepoetin alfa)
    - Available across most of the seven major markets and a more convenient dosing schedule for patients
- Shire' s Dynepo (epoetin delta)
  - Drug profile
    - The first recombinant erythropoietin to be produced in human cells
  - Clinical trial data
    - A complete dearth of information relating to Dynepo' s development in cancer-related anemia...
    - ...however, equal efficacy to Epogen/Procrit has been demonstrated in treatment of anemia related to chronic kidney disease
  - Datamonitor comments
    - Ongoing patent litigation with Amgen resulted in delayed European launch of Dynepo, plus a ban on US launch until relevant patents have expired
    - Dynepo' s pricing at a 30% discount to its competitors in Germany means that some off-label use in oncology indications is likely
- Roche' s Mircera (continuous erythropoietin receptor activator)
  - Drug profile
    - A novel erythropoiesis-stimulating agent with several theoretical advantages over competitors
    - Suspension of recruitment into an oncology Phase II due to an imbalance in fatalities across treatment arms
  - Clinical trial data
    - Mircera appears to have dose-dependent clinical activity in anemic NHL patients receiving chemotherapy
    - Phase II results in NSCLC patients support the feasibility of extended administration of Mircera
    - Mircera produces a rapid and sustained hemoglobin response in multiple myeloma patients
  - Datamonitor comments
    - Despite potentially negative publicity surrounding suspension of enrollment into the NH19960 study, Mircera' s reputation should remain relatively intact
    - Hurdles put in place by Amgen need to be overcome
    - Entering the EU market is likely to be slightly easier for Roche
    - The entire erythropoietin drug class has come under fire
- Forecasts
- Datamonitor drug assessment summary
  - Future potential of pipeline erythropoeisis-stimulating products
    - Both pipeline erythropoietins are expected to see some off-label use prior to formal approval in oncology indications
CHAPTER 7 PIPELINE ANTI-NEUTROPENIA PRODUCTS ANALYSIS AND FORECASTS
- Pipeline overview
  - The current cancer-related neutropenia pipeline
    - An exceedingly sparse pipeline means any threat to currently marketed products is minimal
CHAPTER 8 PIPELINE ANTI-THROMBOCYTOPENIA PRODUCTS ANALYSIS AND FORECASTS
- Pipeline overview
- Definition of current comparator
  - Wyeth' s Neumega (oprelvekin)
    - Chosen only due to the complete lack of other commercially approved products in this indication
- GlaxoSmithKline/Ligand Pharmaceuticals' Promacta (eltrombopag)
  - Drug profile
    - Promacta' s oral availability may represent a significant advantage
  - Clinical trial data
    - Early trial data demonstrates Promacta' s ability to boost platelet levels in cancer patients undergoing chemotherapy, but fails to meet primary endpoint
    - Positive Phase III data in other indications mean that theoretically, Promacta should confer efficacy in cancer-related thrombocytopenia
  - Datamonitor comments
    - A severe lack of approved agents for the prevention and/or treatment of cancer-related thrombocytopenia provides opportunity
    - A gap in the market exists for a product such as Promacta, which GlaxoSmithKline should take full advantage of
- Amgen' s AMG-531
  - Drug profile
    - A novel drug designed to specifically target the thrombopoietin receptor
  - Clinical trial data
    - No cancer-specific study data exist, making it difficult to judge AMG-531' s potential in this patient population
  - Datamonitor comments
    - Amgen' s leading status in the oncology supportive care market will prove invaluable for AMG-531
- Forecasts
- Datamonitor drug assessment summary
  - Future potential of pipeline anti-thrombocytopenia products
    - Following initial off-label use in oncology indications, the anti-thrombocytopenia pipeline products are forecast to enjoy significant sales
CHAPTER 9 PIPELINE ANTI-MUCOSITIS PRODUCTS ANALYSIS AND FORECASTS
- Pipeline overview
- Definition of current comparator
  - Amgen' s Kepivance (palifermin)
    - Chosen only due to the complete lack of other commercially approved products in this indication
- MGI Pharma' s Saforis (L-glutamine)
  - Drug profile
    - Increasing availability of L-glutamine in the oral mucosa may prevent the onset of mucositis
  - Clinical trial data
    - Phase III trial results showing Saforis is capable of significantly reducing the incidence of oral mucositis forms the basis for NDA submission
    - Earlier Phase III results show Saforis appears to reduce the incidence of oral mucositis
  - Datamonitor comments
    - Cost and route of administration of Amgen' s Kepivance places Saforis at a significant advantage
- Forecasts
- Datamonitor drug assessment summary
  - Future potential of pipeline anti-mucositis products
    - A relatively low level of peak sales are deceptive in the face of reasonable uptake of Saforis in cancer-releated mucositis
CHAPTER 10 PIPELINE CANCER-RELATED SKELETAL EVENTS PRODUCTS ANALYSIS AND FORECASTS
- Pipeline overview
- Definition of current comparator
  - Novartis' s Zometa (zoledronate)
    - The leading bisphosphonate for the prevention and/or treatment of cancer-related skeletal events
- Amgen' s denosumab (AMG-162)
  - Drug profile
    - The first targeted therapy for cancer-related skeletal events
  - Clinical trial data
    - Interim results show denosumab to be at least as effective as intravenous bisphosphonates in reducing the risk of cancer-related skeletal events
    - Interim results show denosumab normalizes bone turnover more frequently than intravenous bisphosphonates
  - Datamonitor comments
    - By virtue of its monoclonal antibody formulation, denosumab is likely to be more expensive than currently marketed bisphosphonates...
    - ...however, its lack of association with osteonecrosis of the jaw may work in its favor
    - Amgen' s experience represents a major advantage for denosumab
- Forecasts
- Datamonitor drug assessment summary
  - Future potential of pipeline cancer-related skeletal events products
    - Denosumab theoretically confers several advantages over currently available bisphosphonates, therefore uptake and accompanying sales are forecast to be encouraging
CHAPTER 11 COMMERCIAL IMPACT AND LIFECYCLE MANAGEMENT: CASE STUDY
- The changing oncology supportive care market
  - Current areas of commercial opportunity
    - Several areas of supportive care are drastically underserved at present
    - Potentially increasing range of use for current products
  - Increasing use of targeted therapies
    - A shift towards increased use of molecular targeted therapies will introduce new supportive care challenges
    - New supportive care measures need to be developed, thereby providing significant commercial opportunity...
    - ...yet, it could be that the high cost of the targeted therapies will result in hampered uptake of supportive care products
  - The threat of biosimilars
    - The biologic supportive care products will no longer be protected from generic competition
    - Some biosimilar products can be launched in the EU immediately...
    - ...however, the US is lagging behind
    - The high cost of some supportive care products inhibits their use, indicating a great desire for cheaper biosimilar versions...
    - ...although biosimilar drugs bring with them a new set of issues
  - Increased safety concerns in future
    - As seen with the erythropoeitins class, increased vigilance with respect to safety may be enforced in the future
  - How the oncology supportive care market will change
    - On the whole, the oncology supportive care market will undergo positive growth...
    - ...albeit at a minimal growth rate, due to a lack of major innovation
    - Future growth is likely to come from those early-phase products targeting new supportive care indications
APPENDIX A - MARKET DATA AND MAJOR BRAND KEY FACTS
- A4A (anti-emetics and anti-nauseants) class market data
- B3C (erythropoiesis-stimulating products) class market data
- L3A1 (colony-stimulating factors) class market data
- L3A9 (other immunostimulating agents) class market data
- M5B1/M5B2 (oral and injectable bisphosphonates) class market data
- V3D0 (other detoxifying agents for cancer) class market data
- Sales data and forecasts
- PowerPoint Executive Presentation
APPENDIX B - SALES FORECASTS
- US forecasts
- Japan forecasts
- France forecasts
- Germany forecasts
- Italy forecasts
- Spain forecasts
- UK forecasts
- Five major European markets (EU5) forecasts
- Seven major market forecasts
APPENDIX C
- Bibliography
- List of tables
- List of figures
- Methodology
  - Datamonitor forecast methodology
    - Forecasts for marketed drugs
    - Forecasts for pipeline drugs
  - Datamonitor drug assessment methodology
- About Datamonitor
  - About Datamonitor Healthcare
  - About the Oncology analysis team
- Disclaimer
- List of Tables
  - Table 1: Late-phase oncology supportive care pipeline, 2007
  - Table 2: Phase II oncology supportive care pipeline, 2007
  - Table 3: Phase I oncology supportive care pipeline, 2007
  - Table 4: Supportive care pipeline split by phase and indication, 2007
  - Table 5: Amgen' s marketed oncology supportive care portfolio, 2007
  - Table 6: Amgen' s pipeline oncology supportive care portfolio, 2007
  - Table 7: GlaxoSmithKline' s marketed oncology supportive care portfolio, 2007
  - Table 8: GlaxoSmithKline' s pipeline oncology supportive care portfolio, 2007
  - Table 9: Roche' s marketed oncology supportive care portfolio, 2007
  - Table 10: Roche' s pipeline oncology supportive care portfolio, 2007
  - Table 11: Late-phase pipeline oncology supportive care products sales forecasts ($m), 2007-16
  - Table 12: Marketed 5-HT3 receptor antagonists, 2007
  - Table 13: Marketed erythropoiesis-stimulating products, 2007
  - Table 14: Marketed colony-stimulating factors, 2007
  - Table 15: Marketed bisphosphonates approved for oncology indications, 2007
  - Table 16: Seven major market sales of marketed supportive care products by drug class, 2006
  - Table 17: Key anti-emetics in the oncology supportive care market across the seven major markets, 2007
  - Table 18: Key erythropoiesis-stimulating products in the oncology supportive care market across the seven major markets, 2007
  - Table 19: Key colony-stimulating factors in the oncology supportive care market across the seven major markets, 2007
  - Table 20: Key bisphosphonates in the oncology supportive care market across the seven major markets, 2007
  - Table 21: Other key products in the oncology supportive care market across the seven major markets, 2007
  - Table 22: Crude incidence rates of cancer by gender per 100,000 in the seven major pharmaceutical markets, 2002
  - Table 23: Forecast incidence of cancer across the seven major markets, 2001-15
  - Table 24: Proportion of patients receiving anti-emetics for chemotherapy-induced nausea and vomiting, 2006
  - Table 25: Proportion of patients receiving bisphosphonates for cancer-related skeletal events, 2006
  - Table 26: Generic pricing and erosion assumptions, 2007
  - Table 27: Aloxi versus Zofran: response rates from a Phase III trial to prevent CINV from moderately-emetogenic chemotherapy
  - Table 28: Aloxi versus Zofran: response rates from a Phase III trial to prevent CINV from highly-emetogenic chemotherapy
  - Table 29: Emend in a Phase III trial to prevent CINV from moderately-emetogenic chemotherapy
  - Table 30: Emend in a Phase III trial to prevent CINV from highly-emetogenic chemotherapy
  - Table 31: Fosaprepitant and Emend in a Phase III trial to prevent chemotherapy-induced nausea and vomiting from highly-emetogenic chemotherapy
  - Table 32: Relative potencies of the commercially available bisphosphonates
  - Table 33: Ongoing development for Actonel in oncology indications, 2007
  - Table 34: Approval information for Bondronat/Bonviva/Boniva
  - Table 35: Ongoing clinical development for Bondronat, 2007
  - Table 36: Average physician preference for use of Bondronat in oncology indications across the seven major markets, 2006
  - Table 37: Ongoing Phase III clinical development for Zometa, 2007
  - Table 38: Ongoing clinical development for Kepivance, 2007
  - Table 39: Late-phase anti-emetics for chemotherapy-induced nausea and vomiting pipeline, 2007
  - Table 40: Phase I/II anti-emetics for chemotherapy-induced nausea and vomiting pipeline, 2007
  - Table 41: Results from the Phase II study investigating three different doses of APF-530
  - Table 42: Clinical trials investigating casopitant in chemotherapy-induced nausea and vomiting, 2007
  - Table 43: Treatment arms in a Phase II study investigating casopitant in the prevention of nausea and vomiting from moderately-emetogenic chemotherapy
  - Table 44: Results from a Phase II study investigating casopitant in the prevention of nausea and vomiting from moderately-emetogenic chemotherapy
  - Table 45: Treatment arms in a Phase II study investigating casopitant in the prevention of nausea and vomiting from highly-emetogenic chemotherapy
  - Table 46: Results from a Phase II study investigating casopitant in the prevention of nausea and vomiting from highly-emetogenic chemotherapy
  - Table 47: Pipeline anti-emetic products forecasting assumptions (1 of 2)
  - Table 48: Pipeline anti-emetic products forecasting assumptions (2 of 2)
  - Table 49: Pipeline anti-emetic products sales forecasts ($m), 2007-16
  - Table 50: Erythropoiesis-stimulating products pipeline, 2007
  - Table 51: Results from the BA16728 Phase II study investigating varying doses of Mircera in NHL patients
  - Table 52: Results from the NA17101 Phase II study investigating varying doses of Mircera in NSCLC patients
  - Table 53: Pipeline erythropoiesis-stimulating agents forecasting assumptions
  - Table 54: Pipeline erythropoiesis-stimulating agents sales forecasts ($m), 2007-16
  - Table 55: Anti-neutropenia products pipeline, 2007
  - Table 56: Anti-thrombocytopenia products pipeline, 2007
  - Table 57: Clinical trials investigating AMG-531 in cancer-related thrombocytopenia, 2007
  - Table 58: Pipeline anti-thrombocytopenia products forecasting assumptions
  - Table 59: Pipeline anti-thrombocytopenia products sales forecasts ($m), 2007-16
  - Table 60: Anti-mucositis products pipeline, 2007
  - Table 61: Results from a Phase III study investigating Saforis in breast cancer patients
  - Table 62: Results from a Phase III study investigating Saforis in cancer patients
  - Table 63: Pipeline anti-mucositis products forecasting assumptions
  - Table 64: Pipeline anti-mucositis products sales forecasts ($m), 2007-16
  - Table 65: Cancer-related skeletal events products pipeline, 2007
  - Table 66: Phase III clinical trials investigating denosumab in oncology, 2007
  - Table 67: Phase II clinical trials investigating denosumab in oncology, 2007
  - Table 68: Interim results from study investigating denosumab in bisphosphonate-naïve metastatic breast cancer patients
  - Table 69: Interim results from study investigating denosumab in advanced cancer patients who had received prior bisphosphonate therapy, 2006
  - Table 70: Pipeline cancer-related skeletal events products forecasting assumptions
  - Table 71: Pipeline cancer-related skeletal events products sales forecasts ($m), 2007-16
  - Table 72: Products in development for currently unmet supportive care challenges, 2007
  - Table 73: Common side effects associated with the molecular targeted therapies
  - Table 74: Products in development for new supportive care challenges, 2007
  - Table 75: Oncology supportive care market forecast sales, 2006-16
  - Table 76: Aloxi: key facts
  - Table 77: Anzemet: key facts
  - Table 78: Emend: key facts
  - Table 79: Kytril: key facts
  - Table 80: Nasea: key facts
  - Table 81: Navoban: key facts
  - Table 82: Serotone: key facts
  - Table 83: Sinseron: key facts
  - Table 84: Zofran: key facts
  - Table 85: Aranesp: key facts
  - Table 86: Epogen/Procrit: key facts
  - Table 87: NeoRecormon: key facts
  - Table 88: Granocyte: key facts
  - Table 89: Leukine: key facts
  - Table 90: Neulasta: key facts
  - Table 91: Neupogen: key facts
  - Table 92: Neu-Up: key facts
  - Table 93: Neumega: key facts
  - Table 94: Actonel: key facts
  - Table 95: Aredia: key facts
  - Table 96: Bisphonal: key facts
  - Table 97: Bondronat: key facts
  - Table 98: Bonefos: key facts
  - Table 99: Zometa: key facts
  - Table 100: Kepivance: key facts
  - Table 101: Marketed supportive care product forecasts in the US, 2006-16 (1 of 3)
  - Table 102: Marketed supportive care product forecasts in the US, 2006-16 (2 of 3)
  - Table 103: Marketed supportive care product forecasts in the US, 2006-16 (3 of 3)
  - Table 104: Marketed supportive care product forecasts in Japan, 2006-16 (1 of 3)
  - Table 105: Marketed supportive care product forecasts in Japan, 2006-16 (2 of 3)
  - Table 106: Marketed supportive care product forecasts in Japan, 2006-16 (3 of 3)
  - Table 107: Marketed supportive care product forecasts in France, 2006-16 (1 of 3)
  - Table 108: Marketed supportive care product forecasts in France, 2006-16 (2 of 3)
  - Table 109: Marketed supportive care product forecasts in France, 2006-16 (3 of 3)
  - Table 110: Marketed supportive care product forecasts in Germany, 2006-16 (1 of 3)
  - Table 111: Marketed supportive care product forecasts in Germany, 2006-16 (2 of 3)
  - Table 112: Marketed supportive care product forecasts in Germany, 2006-16 (3 of 3)
  - Table 113: Marketed supportive care product forecasts in Italy, 2006-16 (1 of 3)
  - Table 114: Marketed supportive care product forecasts in Italy, 2006-16 (2 of 3)
  - Table 115: Marketed supportive care product forecasts in Italy, 2006-16 (3 of 3)
  - Table 116: Marketed supportive care product forecasts in Spain, 2006-16 (1 of 3)
  - Table 117: Marketed supportive care product forecasts in Spain, 2006-16 (2 of 3)
  - Table 118: Marketed supportive care product forecasts in Spain, 2006-16 (3 of 3)
  - Table 119: Marketed supportive care product forecasts in the UK, 2006-16 (1 of 3)
  - Table 120: Marketed supportive care product forecasts in the UK, 2006-16 (2 of 3)
  - Table 121: Marketed supportive care product forecasts in the UK, 2006-16 (3 of 3)
  - Table 122: Marketed supportive care product forecasts in the EU5, 2006-16 (1 of 3)
  - Table 123: Marketed supportive care product forecasts in the EU5, 2006-16 (2 of 3)
  - Table 124: Marketed supportive care product forecasts in the EU5, 2006-16 (3 of 3)
  - Table 125: Marketed supportive care product forecasts across the seven major markets, 2006-16 (1 of 4)
  - Table 126: Marketed supportive care product forecasts across the seven major markets, 2006-16 (2 of 4)
  - Table 127: Marketed supportive care product forecasts across the seven major markets, 2006-16 (3 of 4)
  - Table 128: Marketed supportive care product forecasts across the seven major markets, 2006-16 (4 of 4)
  - Table 129: Datamonitor drug assessment parameters
- List of Figures
  - Figure 1: Supportive care pipeline split by phase and indication, 2007
  - Figure 2: Supportive care pipeline split by phase, 2007
  - Figure 3: Supportive care pipeline split by indication, 2007
  - Figure 4: Supportive care pipeline split by company, 2007
  - Figure 5: Pipeline anti-emetic products sales forecasts in the oncology supportive care market ($m), 2007-16
  - Figure 6: Pipeline erythropoiesis-stimulating agents sales forecasts in the oncology supportive care market ($m), 2007-16
  - Figure 7: Pipeline anti-thrombocytopenia products sales forecasts in the oncology supportive care market ($m), 2007-16
  - Figure 8: Pipeline anti-mucositis products sales forecasts in the oncology supportive care market ($m), 2007-16
  - Figure 9: Pipeline cancer-related skeletal events products sales forecasts in the oncology supportive care market ($m), 2007-16
  - Figure 10: Datamonitor drug assessment summary for the pipeline anti-emetics in the oncology supportive care market, 2007
  - Figure 11: Datamonitor drug assessment summary for the pipeline erythropoiesis-stimulating products in the oncology supportive care market, 2007
  - Figure 12: Datamonitor drug assessment summary for the pipeline anti-thrombocytopenia products in the oncology supportive care market, 2007
  - Figure 13: Datamonitor drug assessment summary for the pipeline anti-mucositis products in the oncology supportive care market, 2007
  - Figure 14: Datamonitor drug assessment summary for the pipeline cancer-related skeletal events products in the oncology supportive care market, 2007
  - Figure 15: Forecast incidence of cancer across the seven major markets, 2001-15
  - Figure 16: Pipeline anti-emetic products sales forecasts ($m), 2007-16
  - Figure 17: Datamonitor drug assessment summary for the pipeline anti-emetics, 2007
  - Figure 18: Pipeline erythropoiesis-stimulating agents sales forecasts ($m), 2007-16
  - Figure 19: Datamonitor drug assessment summary for the pipeline erythropoiesis-stimulating products, 2007
  - Figure 20: Pipeline anti-thrombocytopenia products sales forecasts ($m), 2007-16
  - Figure 21: Datamonitor drug assessment summary for the pipeline anti-thrombocytopenia products, 2007
  - Figure 22: Pipeline anti-mucositis products sales forecasts ($m), 2007-16
  - Figure 23: Datamonitor drug assessment summary for the pipeline anti-mucositis products, 2007
  - Figure 24: Pipeline cancer-related skeletal events products sales forecasts ($m), 2007-16
  - Figure 25: Datamonitor drug assessment summary for the pipeline cancer-related skeletal events products, 2007
  - Figure 26: Oncology supportive care market forecast sales, 2006-16
  - Figure 27: Datamonitor drug assessment summary for the pipeline cancer-related skeletal events products, 2007

Pipeline/Commercial Insight: Supportive Care in Oncology - Significant growth opportunities exist in new supportive care indications

Table of Contents